Our Leadership

In a short period of time, TransCelerate has achieved unprecedented progress, delivering tangible impact to benefit the broader biopharmaceutical industry. All this would not have been achievable without the active engagement and sponsorship from some of the most senior leaders in the industry.

In just a few years, our leaders have made significant strides toward our goal of making clinical development more efficient. TransCelerate leadership has an unwavering dedication to assessing, refining and creating processes to make the drug development environment efficient, safe and innovative.

Corporate Leadership

Ülo Palm
Secretary and Oversight Committee Chair, TransCelerate; SVP, Drug Development Operations, Allergan
Andy Lee
Treasurer, TransCelerate; SVP, Head of Global Clinical Trial Operations, Merck
Janice Chang
EVP, TransCelerate BioPharmaceutical Inc.

Board of Directors

Dalvir Gill
CEO, TransCelerate BioPharma Inc.
Elliott Levy
Chair of the Board, SVP, Global Development, Amgen
David Nicholson
Vice Chair of the Board, EVP and Chief R&D Officer, Allergan
Roy Baynes
SVP, Global Clinical Development, Merck Research Laboratories
Sean Bohen
EVP, Global Medicines Development, and Chief Medical Officer, AstraZeneca Pharmaceuticals
Iris Loew-Friedrich
Rod MacKenzie
EVP, Chief Development Officer, Pfizer Inc.
Robert Metcalf
Vice President, Clinical Development Organization, Eli Lilly and Company
Kate Owen
Head of Global Clinical Operations (GCO), Bristol-Myers Squibb
John Reed
President, Global Research & Development, Sanofi
Michelle Rohrer
SVP, Global Head of Pharma Regulatory and Policy, Roche
Takuko Sawada
Director, EVP, Shionogi & Co., Ltd.
Rob Scott
CMO, AbbVie
Badhri Srinivasan
Head, Global Development Operations, Novartis
Paul Stoffels
Vice Chair of the Executive Committee and Chief Scientific Officer
Bernhardt Zeiher
Chief Medical Officer and President, Development, Astellas Pharma